Colgate Palmolive (CL) Share Value Declined While Wellington Shields Capital Management Has Boosted Its Position; Regeneron Pharmaceuticals (REGN) Shareholder Pinnacle Associates LTD Has Decreased Position by $7.26 Million

April 22, 2018 - By Migdalia James

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Pinnacle Associates Ltd decreased its stake in Regeneron Pharmaceuticals (REGN) by 7.33% based on its latest 2017Q4 regulatory filing with the SEC. Pinnacle Associates Ltd sold 19,349 shares as the company’s stock declined 13.59% with the market. The institutional investor held 244,758 shares of the health care company at the end of 2017Q4, valued at $92.02M, down from 264,107 at the end of the previous reported quarter. Pinnacle Associates Ltd who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be less bullish one the $33.81B market cap company. The stock decreased 0.50% or $1.58 during the last trading session, reaching $314.25. About 688,735 shares traded. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has declined 14.19% since April 22, 2017 and is downtrending. It has underperformed by 25.74% the S&P500.

Wellington Shields Capital Management Llc increased its stake in Colgate Palmolive (CL) by 80.04% based on its latest 2017Q4 regulatory filing with the SEC. Wellington Shields Capital Management Llc bought 4,522 shares as the company’s stock declined 7.81% with the market. The institutional investor held 10,172 shares of the package goods and cosmetics company at the end of 2017Q4, valued at $767,000, up from 5,650 at the end of the previous reported quarter. Wellington Shields Capital Management Llc who had been investing in Colgate Palmolive for a number of months, seems to be bullish on the $58.97 billion market cap company. The stock decreased 3.22% or $2.25 during the last trading session, reaching $67.52. About 8.64 million shares traded or 105.62% up from the average. Colgate-Palmolive Company (NYSE:CL) has declined 5.65% since April 22, 2017 and is downtrending. It has underperformed by 17.20% the S&P500.

Investors sentiment decreased to 0.87 in Q4 2017. Its down 0.03, from 0.9 in 2017Q3. It worsened, as 56 investors sold CL shares while 444 reduced holdings. 98 funds opened positions while 335 raised stakes. 606.34 million shares or 1.77% less from 617.24 million shares in 2017Q3 were reported. Victory Cap reported 58,107 shares. Washington Trust invested in 11,035 shares or 0.05% of the stock. Aperio Gp Limited Co has 533,770 shares for 0.21% of their portfolio. Tower Bridge Advsr holds 0.72% of its portfolio in Colgate-Palmolive Company (NYSE:CL) for 89,297 shares. Mariner Wealth Advisors Ltd Liability accumulated 31,907 shares or 0.09% of the stock. Wellington Shields Mngmt Ltd Llc has invested 0.12% of its portfolio in Colgate-Palmolive Company (NYSE:CL). Johnson Financial Grp Inc Inc has 12,676 shares. Financial Architects holds 0.06% or 5,076 shares. Campbell Newman Asset Management holds 14,685 shares or 0.19% of its portfolio. C Gru Hldg A S invested in 416,148 shares. Adams Diversified Equity Fund Incorporated has 0.64% invested in Colgate-Palmolive Company (NYSE:CL) for 156,600 shares. Penobscot Mgmt Company has invested 0.18% in Colgate-Palmolive Company (NYSE:CL). Crystal Rock Cap holds 1.34% or 27,500 shares. Stock Yards Commercial Bank And Trust, Kentucky-based fund reported 9,244 shares. Asset Advsrs Corp stated it has 2,670 shares.

Wellington Shields Capital Management Llc, which manages about $901.02M and $644.18 million US Long portfolio, decreased its stake in Chimera Invt Corp New by 18,250 shares to 18,300 shares, valued at $338,000 in 2017Q4, according to the filing. It also reduced its holding in At&T Inc (NYSE:T) by 26,643 shares in the quarter, leaving it with 176,150 shares, and cut its stake in Nike (NYSE:NKE).

Among 25 analysts covering Colgate-Palmolive (NYSE:CL), 6 have Buy rating, 1 Sell and 18 Hold. Therefore 24% are positive. Colgate-Palmolive had 68 analyst reports since July 21, 2015 according to SRatingsIntel. Citigroup maintained Colgate-Palmolive Company (NYSE:CL) rating on Friday, July 29. Citigroup has “Buy” rating and $88 target. The stock of Colgate-Palmolive Company (NYSE:CL) has “Overweight” rating given on Tuesday, October 31 by Morgan Stanley. The firm has “Hold” rating by RBC Capital Markets given on Friday, June 30. The stock of Colgate-Palmolive Company (NYSE:CL) earned “Neutral” rating by BNP Paribas on Friday, July 29. The firm has “Hold” rating by Jefferies given on Monday, October 30. The company was maintained on Monday, March 21 by Barclays Capital. The firm has “Hold” rating given on Monday, November 2 by Deutsche Bank. The rating was upgraded by BNP Paribas on Friday, January 15 to “Outperform”. The firm has “Hold” rating given on Friday, October 6 by RBC Capital Markets. As per Friday, April 20, the company rating was maintained by Morgan Stanley.

Since December 13, 2017, it had 0 insider buys, and 20 selling transactions for $32.94 million activity. Another trade for 7,375 shares valued at $539,694 was made by Daniels Jennifer on Wednesday, December 13. Another trade for 4,584 shares valued at $321,701 was sold by Wallace Noel R.. HICKEY DENNIS J sold $396,561 worth of stock. 14,000 Colgate-Palmolive Company (NYSE:CL) shares with value of $972,125 were sold by HUSTON JOHN J. 5,692 shares were sold by Marsili Daniel B, worth $399,530 on Tuesday, February 20. MOISON FRANCK J had sold 10,000 shares worth $705,797.

Investors sentiment is 1.17 in 2017 Q4. Its the same as in 2017Q3. It is the same, as 62 investors sold REGN shares while 161 reduced holdings. only 71 funds opened positions while 191 raised stakes. 69.17 million shares or 6.15% less from 73.70 million shares in 2017Q3 were reported. Envestnet Asset Mgmt Incorporated owns 22,855 shares. Meiji Yasuda Asset Mgmt Limited holds 1,677 shares. Glenmede Tru Com Na invested in 7,019 shares. Gemmer Asset Ltd Liability holds 0.02% or 180 shares in its portfolio. Loeb reported 0.17% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Hennessy holds 2,010 shares. 14,837 are held by Zurcher Kantonalbank (Zurich Cantonalbank). The Illinois-based Blair William & Co Il has invested 0.01% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Norinchukin Commercial Bank The stated it has 6,160 shares. Clinton Grp Incorporated holds 0.18% or 5,324 shares in its portfolio. Andra Ap holds 0.05% or 5,400 shares. Janney Montgomery Scott Llc has 0.02% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 4,747 shares. Weiss Asset Ltd Partnership reported 571 shares. Halsey Associates Ct invested in 1.05% or 16,347 shares. Landscape Capital Mngmt Ltd has 0.07% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 2,143 shares.

Pinnacle Associates Ltd, which manages about $6.31B and $5.20B US Long portfolio, upped its stake in Biogen Inc (NASDAQ:BIIB) by 4,091 shares to 13,343 shares, valued at $4.25M in 2017Q4, according to the filing. It also increased its holding in Johnson & Johnson (NYSE:JNJ) by 4,223 shares in the quarter, for a total of 206,724 shares, and has risen its stake in Ishares Tr (IVV).

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on May, 3 before the open. They expect $5.08 EPS, up 135.19% or $2.92 from last year’s $2.16 per share. REGN’s profit will be $546.59M for 15.47 P/E if the $5.08 EPS becomes a reality. After $4.46 actual EPS reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 13.90% EPS growth.

Colgate-Palmolive Company (NYSE:CL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts